Suppr超能文献

具有专用 RNA 聚合酶 II 或 III 活性的工程化微小 H1 启动子。

Engineered miniature H1 promoters with dedicated RNA polymerase II or III activity.

机构信息

Laboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Biomedicine, Aarhus University, Aarhus, Denmark.

Laboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

出版信息

J Biol Chem. 2021 Jan-Jun;296:100026. doi: 10.1074/jbc.RA120.015386. Epub 2020 Nov 23.

Abstract

RNA polymerase III (Pol III) promoters, such as 7SK, U6, and H1, are widely used for the expression of small noncoding RNAs, including short hairpin RNAs for RNAi experiments and guide RNAs for CRISPR-mediated genome editing. We previously reported dual RNA polymerase activity (Pol II/III) for the human H1 promoter and demonstrated that this promiscuous RNA polymerase use can be exploited for the simultaneous expression of both a noncoding RNA and an mRNA. However, this combination is not a desired feature in other experimental and therapeutic settings. To overcome this limitation of the H1 promoter, we engineered a miniature H1/7SK hybrid promoter with minimal Pol II activity, thereby boosting Pol III activity to a level that is higher than that of either parental promoter. In parallel, we also engineered small Pol II-specific H1 promoter variants and explored their use as general Pol II promoters for protein expression. The newly engineered promoter variants form an attractive alternative to the commonly used H1 promoter in terms of not only activity and small promoter size but also concerning safety by exclusive expression of the desired therapeutic transcript (either pol II or pol III but not both).

摘要

RNA 聚合酶 III(Pol III)启动子,如 7SK、U6 和 H1,广泛用于小非编码 RNA 的表达,包括用于 RNAi 实验的短发夹 RNA 和用于 CRISPR 介导的基因组编辑的指导 RNA。我们之前报道了人类 H1 启动子的双重 RNA 聚合酶活性(Pol II/III),并证明这种混杂的 RNA 聚合酶利用可以用于同时表达非编码 RNA 和 mRNA。然而,在其他实验和治疗环境中,这种组合并不是一个理想的特征。为了克服 H1 启动子的这个限制,我们设计了一个具有最小 Pol II 活性的微型 H1/7SK 杂交启动子,从而将 Pol III 活性提高到高于任何亲本启动子的水平。同时,我们还设计了一些小的 Pol II 特异性 H1 启动子变体,并探索了它们作为用于蛋白质表达的通用 Pol II 启动子的用途。就活性和小启动子大小而言,新设计的启动子变体不仅是一种有吸引力的替代方案,而且在安全性方面,它们只表达所需的治疗性转录本(Pol II 或 Pol III,但不是两者都有)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b040/7949045/bfc183fbe82a/gr3.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验